NovoCure Limited (NVCR) Total liabilities 2017–2026
NovoCure Limited (NVCR) total liabilities at each fiscal year-end, per SEC filings.
$463.9MFY2026 · since FY2017: $139.7M → $463.9M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | $463.9M | -47.3% |
| FY2025 | $880.6M | +12.4% |
| FY2024 | $783.6M | +4.4% |
| FY2023 | $750.5M | +2.9% |
| FY2022 | $729.0M | +26.7% |
| FY2021 | $575.5M | +119.9% |
| FY2020 | $261.7M | +15.0% |
| FY2019 | $227.5M | +50.0% |
| FY2018 | $151.7M | +8.6% |
| FY2017 | $139.7M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More NVCR financial trends
NVCR RevenueNVCR Net incomeNVCR Net marginNVCR Gross profitNVCR Gross marginNVCR Operating incomeNVCR Operating marginNVCR Operating cash flowNVCR Free cash flowNVCR Capital expendituresNVCR Return on equityNVCR Stock buybacksNVCR Dividends paidNVCR Total assetsNVCR Shareholders’ equityNVCR overview →